Syndecan-binding protein 1 (SDCBP) (SDCBP)

Syndecan-binding protein 1 (SDCBP), commonly known as MDA-9 or Syntenin-1, is a multifunctional adaptor protein that plays a pivotal role in organizing protein complexes at the plasma membrane through its two tandem PDZ domains (Das et al., 2020). The PDZ2 domain is a critical functional module that mediates high-affinity interactions with the C-terminal motifs of various partners, including syndecans, c-Src, and Frizzled 7, thereby organizing signaling complexes essential for cell motility and trafficking (Leblanc et al., 2016; Pradhan et al., 2021). In many human cancers, such as melanoma and glioblastoma, MDA-9/Syntenin is significantly overexpressed and serves as a key driver of tumor invasion, angiogenesis, and metastasis by facilitating the activation of the Src/FAK and NF-κB signaling axes (Kegelman et al., 2015). Therapeutic strategies targeting the PDZ2 domain, including dual-PDZ inhibitors like IVMT-Rx-3, aim to disrupt these oncogenic protein-protein interactions to suppress the metastatic phenotype (Pradhan et al., 2021). Beyond its role in oncology, the protein is a key regulator of exosome biogenesis and trafficking, which are essential for intercellular communication (Das et al., 2020). Although it has diverse physiological roles, preclinical evidence from knockout studies suggests that its pharmacological inhibition is well-tolerated, highlighting its potential as a viable target for aggressive malignancies (Das et al., 2020).

Other names

MDA-9Syntenin-1SDCBPMelanoma differentiation-associated gene 9Pro-TGF-alpha cytoplasmic domain-interacting protein 1 (TACIP1)

Inhibition of protein-protein interactions (PPIs) by binding to the PDZ2 domain, preventing the recruitment of signaling partners such as c-Src and Frizzled 7, which blocks downstream oncogenic signaling pathways like NF-κB and MAPK.